期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

C末端抗利尿激素前体片段是评价急性冠状动脉综合征患者的一个新标记物 被引量：1

暂未订购
导出
摘要 急性冠状动脉综合征（ACS）是严重威胁人类生命健康的重大疾病。近年来，我国的冠心病发病率、住院率和院前死亡率持续攀升。目前每年有〉70万人死于冠心病，1998-2008年间，我国男性冠心病发病率增加26．1％，女性冠心病发病率增加19％[1]。C末端抗利尿激素前体片段也称为和肽素（copeptin），是下丘脑和垂体合成和释放的一种神经肽，它由39个氨基酸残基所组成。在发生急性心肌损伤时，血和肽素水平急剧升高，它较心肌酶、肌红蛋白和肌钙蛋白（cTn）等已知心肌损伤标记物的变化，发生的更早、更快、更明显[2]。特别是急性心肌梗死（AMI）的早期诊断、危险分层、预后评估及治疗策略方面的应用价值，已成为近年心血管病领域研究的热点之一。和肽素对ACS诊疗价值的现状如何，存在哪些争论？近期陆续发表的几项研究，用部分临床证据对其进行了初步解答和探索。
作者 郑刚
机构地区 天津市第三医院心内科天津市老年病研究所
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2013年第6期658-660,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 急性冠状动脉综合征 血管升压素类 生物学标记 和肽素 早期诊断
分类号 R543.3 [医药卫生—心血管疾病]
  • 相关文献

参考文献20

  • 1孙佳艺,刘静,谢学勤,韦再华,王薇,王淼,齐玥,刘军,郭默宁,张秀英,万浩,赵冬.2007至2009年北京市25岁以上居民急性冠心病事件发病率的监测[J].中华心血管病杂志,2012,40(3):194-198. 被引量：70
  • 2Lippi G, Plebani M, Di Somma S, et al. Considerations for ear1 ly acute myocardial infarction rule out for emergency depart ment chest pain patients:the case of copeptin. Clin Chem La Med,2012,50:243-253. 1.
  • 3Nickel CH, Bingisser R, Morgenthaler NG. The role of copep tin as a diagnostic and prognostic biomarker for risk stratifica tion in the emergency department. BMC Med, 2012,10 7.
  • 4Katan M, Christ Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly, 2010,140:w13101.
  • 5Bhandari SS,Loke I,Davies JE,et al. Gender and renal func- tion influence plasma levels of eopeptin in healthy individuals. Clin Sci (I.ond) ,2009,116:257 263.
  • 6Meune C, Zuily S, Wahbi K, et al. Combination of copeptin and high sensitivity cardiac troponin T assay in unstable angi na and non ST segment elevation myocardial infarction: a pi lot study. Arch Cardiovasc Dis,2011,104:4 10.
  • 7Giannitsis E, Kehayova T, Vafaie M, et al. Combined testing of high-sensitivity troponin T and copeptin on presentation at prespeeified cutoffs improves rapid rule out of nonST seg ment elevation myocardial infarction. Clin Chem, 2011,57: 1452 1455.
  • 8Charpentier S, Maupas-Schwalm F, Cournot M, et al. Combi nation of copeptln and troponin assays to rapidly rule out non ST elevation myocardial infarction in the emergency depart ment. Acad Emerg Med, 2012,19 : 517 524.
  • 9Karakas M,Januzzi JL Jr, Meyer J,et al. Copeptin does not add diagnostic information to high sensitivity troponin T in low- to intermediaterisk patients with acute chest pain: re- sults from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem, 2011,57 = 1137 1145.
  • 10Narayan H, Dhillon OS, Quinn PA, et al. C terminal provaso pressin (copeptin) as a prognostic marker after acute non ST elevation myocardial infarction: Leicester acute myocardial in faretion peptide [I (LAMP 11 ) study. Clin Sei (Lond), 2011, 121:79 89.

二级参考文献6

共引文献69

同被引文献18

  • 1Chen J, Dharmarajan K, Wang Y, et al. National trends in heart failure hospital stay rates, 2001 to 2009. J Am Coll Cardiol, 2013,61 : 1078-1088.
  • 2Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Meal,2012,10:7.
  • 3Loncar G, yon Haehling S, Tahirovic E, et al. Effect of beta blockade on natriuretic peptides and copeptin in elderly patients with heart failure and preserved or reduced ejection fraction: re- sults from the CIBIS-ELD trial.Clin Biochem, 2012,45 : 117-122.
  • 4Sahu BS, Mohan J, Sahu G, et al. Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neu- ronal nicotinic aeetylcholine receptor. J Cell Sci,2012,125 (Pt.
  • 5Matusik P, Dubiel M, Wizner B,et al. Age-related gap in the management of heart failure patients. The National Project of Pre- vention and Treatment of Cardiovascular Diseases-POLKARD. Cardiol J,2012,19:146-152.
  • 6Hossain MA, Rosengren K J, Samuel CS, et al. The minimal ac- tive structure of human relaxin-2. J Biol Chem,2011,286: 34555-34565.
  • 7Teerlink JR, Cotter G, Davison BA,et al. For the RELAXIn in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, re- combinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomlsed, placebo-controlled trial. Lancet, 2013,381(9860) :29-39.
  • 8Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on inter-pretation of test results. Am Heart J,2013,165:995-999.
  • 9Erkilet G, Ozpeker C, BOthig D,et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant,2013,32: 221-230.
  • 10Chen K, Jiang ILl, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci,2013,17: 1005-1011.

引证文献1

二级引证文献6

中华老年心脑血管病杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部